BACKGROUND: This study assessed the use of active surveillance in men with low-risk prostate cancer and evaluated institutional factors associated with the receipt of active surveillance. METHODS: A retrospective, hospital-based cohort of 115,208 men with lowrisk prostate cancer diagnosed between 2010 and 2014 was used. Multivariate and mixed effects models were used to examine variation and factors associated with active surveillance. RESULTS: During the study period, the use of active surveillance increased from 6.8% in 2010 to 19.9% in 2014 (estimated annual percentage change, 128.8%; 95% confidence interval [CI], 1 19.6% to 1 38.7%; P 5.002). The adjusted probability of active-surveillance receipt by institution was highly variable. Compared with patients treated at comprehensive community cancer centers, patients treated at community cancer programs (odds ratio [OR], 2.00; 95% CI, 1.50-2.67; P <.001) and academic institutions (OR, 2.47; 95%, CI, 1.81-3.37; P <.001) had higher odds of receiving active surveillance. Compared with patients treated at very low-volume facilities, patients treated at very high-volume facilities had higher odds of receiving active surveillance (OR, 3.57; 95% CI, 1.94-6.55; P <.001). Patient and hospital characteristics accounted for 60.2% of the overall variation, whereas the treating institution accounted for 91.5% of the unexplained variability. CONCLUSIONS: Within this hospital-based cohort, the use of active surveillance for low-risk prostate cancer increased significantly over time. Significant variation was found in the use of active surveillance. Most of the variation was attributable to facility-related factors such as the facility type, facility volume, and institution. Policies to achieve consistent and higher rates of active surveillance, when appropriate, should be a priority of professional societies and patient advocacy groups. Cancer 2018;124:55-64.
INTRODUCTION
For men with low-risk prostate cancer, active surveillance has emerged as a quality of life-preserving alternative to definitive therapy. In contrast to watchful waiting, active surveillance includes a strict protocol of prostate-specific antigen (PSA) testing, physical examination, and repeat prostate biopsies until disease progression is detected, at which point definitive treatment is recommended. Large series originating from pioneer centers have shown promising results with a 10-year cancer-specific survival rate of 97%, with 70% remaining on surveillance during that period. 1, 2 As such, active surveillance is now recommended as a first-line management option for patients with very low-risk prostate cancer (cT1c, Gleason score 6, PSA level < 10 ng/mL, PSA density < 0.15 ng/mL/g, < 3 positive biopsy cores, and 50% cancer in any core) or low-risk prostate cancer (cT1-T2a, Gleason score 6, and PSA level < 10 ng/mL) and with a life expectancy 10 years. 3 Reports on the use of active surveillance for localized prostate cancer have been variable. Although data from the Cancer of the Prostate Strategic Urologic Research Endeavor (CaPSURE) suggest that nearly 50% of eligible men are choosing active surveillance, recent data from population-or hospital-based registries find underuse (in the 10% range) of this modality. [4] [5] [6] [7] The underlying reasons for this difference remain unclear, although the use of active surveillance has been found to correlate with specific demographic (eg, age), socioeconomic (eg, education), and geographic parameters (eg, census division). 7, 8 Moreover, physicianand facility-related factors, such as practice ownership of a surgical robot or radiation therapy equipment, have been inversely associated with the receipt of active surveillance. 7, 9, 10 With the recent passage of US legislation aimed at standardizing validated, high-value clinical care, there is a growing need for studies that identify sources of nonclinical variation across care settings and specialties. 11 Several studies, including a 2013 Institute of Medicine report on sources of variation in health care spending, 12 have implicated unjustified regional and physician-level variation of cancer treatment modalities as a quality-of-care concern. Consequently, we sought to examine the contemporary use of active surveillance and sources of variation in the use of active surveillance. We relied on the National Cancer Data Base (NCDB), a registry of all Commission on Cancer (CoC)-accredited hospitals. 13 Given the pervasive financial and market incentives driving US prostate cancer care, we hypothesize that wide variation exists among institutional active-surveillance practices.
MATERIALS AND METHODS

Data Source
The NCDB, a joint program of the CoC and the American Cancer Society, is a nationwide oncology database that contains information on patterns of cancer care and treatment outcomes. The NCDB collects data on newly diagnosed cancers since 1989 and includes information on more than 29 million cancers from more than 1500 CoC-accredited programs in the United States and Puerto Rico. The CoC accreditation process aims to ensure highquality patient care with an emphasis on patient-centered care. Approximately 70% of newly diagnosed tumors in the United States are reported to the NCDB. 13 
Patient Selection
Men who were 40 to 75 years old and were diagnosed between January 2010 and December 2014 with low-risk (PSA level < 10 ng/mL, Gleason score 6, and clinical stage cT1 to cT2a) adenocarcinoma of the prostate (code C61.9 from International Classification of Diseases for Oncology, 3rd edition) 14 according to National Comprehensive Cancer Network (NCCN) guidelines 3 were eligible for the study. Cases with information missing for the clinical T stage, Gleason score, and PSA were excluded. TNM staging was established on the basis of the AJCC Cancer Staging Manual (7th edition). 15 Our selection criteria ( Fig. 1) yielded 115,208 assessable prostate cancer cases treated at 1194 CoC accredited facilities.
Variable of Interest
Active surveillance was defined per the NCDB variable "RX_SUMM_TREATMENT_STATUS." Patients assigned to code 2 (active surveillance) were considered to have undergone initial active surveillance. Treatment after a period of active surveillance was considered subsequent treatment and was not accounted for in this variable.
Covariates
The baseline patient variables consisted of the following: age at diagnosis (categorized according to quartiles as 40-57, 58-62, 63-67, or 68-75 years), PSA level at diagnosis (continuous), clinical T stage (cT1 vs cT2a), year of diagnosis (2010-2014), race (white, black, or other), median proportion of individuals within the ZIP code without a high school diploma (6.9%, 7%-12.9%, 13%-20.9%, or 21%), median household income within the ZIP code ($37,999, $38,000-$47,999, $48,000-$62,999, or $63,000), urban/rural status (metropolitan, urban county, rural county, or unknown according to ruralurban continuum codes published by the US Department of Agriculture), great circle distance (distance in miles between a patient's residence based on the ZIP code centroid or city and the street address of the facility), and census geographical region (New England, Middle Atlantic, South Atlantic, East North Central, East South Central, West North Central, West South Central, Mountain, or Pacific). 16 Comorbidity was assessed with the Charlson Comorbidity Index and categorized as 0, 1, or 2 as specified by the NCDB. 17 The 
Statistical Analyses
First, frequencies and proportions were reported for categorical variables, whereas medians and interquartile ranges were reported for continuous variables. Bivariate differences in categorical and continuous variables between treatment groups were examined with the Rao-
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Scott chi-square and Wilcoxon tests, respectively, with both accounting for clustering within a facility. 19, 20 Trends in the use of active surveillance over time were assessed with the estimated annual percentage change methodology. 21 Second, a multilevel hierarchical mixed effects logistic regression model was fitted to predict the odds of receiving active surveillance, and individual facilities were considered as a random effect. Fixed covariates (fixed effects) included patient-related factors (age and Charlson Comorbidity Index), sociodemographic factors (race, education, income, urban/rural status, and great circle distance), and facility-related factors (type, census geographical region, and hospital volume). A figure was created on the basis of the adjusted probabilities of receiving active surveillance.
Finally, pseudo-R 2 values derived from the multilevel hierarchical mixed effects logistic regression model were used to assess the relative contributions of patient and hospital variables to the receipt of active surveillance. 22 R 2 represents the relative contribution of the variable in question to the probability of receiving active surveillance. We then repeated our analyses in different populations: 1) the original cohort plus cTx patients and 2) the original cohort plus cT2 patients (because the clinical stage is regarded as a poor discriminator of risk). 23 All analyses were performed with Stata 13 (StataCorp, College Station, Texas) with the 2-sided significance level set at P < .05. An institutional review board waiver from Brigham and Women's Hospital was obtained before this study was performed.
RESULTS
During the study period, 14,180 men with NCCN lowrisk prostate cancer (12.3%) were initially managed with active surveillance. Notably, during that same period, 4200 men elected no treatment, and another 705 underwent an unknown treatment; the latter patients were not included in the other-treatment group. The rate of active surveillance increased significantly from 6.8% in 2010 to 19.9% in 2014 (estimated annual percent change, 128.8%; 95% confidence interval [CI], 1 19.6% to 1 38.7%; P 5 .002). The proportion of men receiving active surveillance varied from 0.0% to 100.0% among the 1194 institutions included in the analysis. Table 1 shows baseline clinical, histological, sociodemographic, and institutional characteristics of the study population stratified by active surveillance and other treatment modalities. Significant differences in treatment patterns were observed among sociodemographic and facilityrelated factors (Table 1) , with older individuals, wealthier individuals, publicly insured individuals, and individuals receiving care at high-volume centers more frequently undergoing active surveillance.
Factors Associated With the Receipt of Active Surveillance
The results of the multivariate logistic regression analysis are presented in Table 2 . Uninsured patients had higher odds of receiving active surveillance (odds ratio [OR], 1.29; 95% CI, 1.09-1.53). Compared with patients treated at comprehensive community cancer programs, patients treated at academic/research programs (OR, 2.47; 95% CI, 1.81-3.37) and community cancer programs (OR, 2.00; 95% CI, 1.50-2.67) had higher odds of receiving active surveillance. With respect to institutional volume, patients receiving care at very high-volume centers had increased odds of undergoing active surveillance in comparison with those receiving care at very lowvolume facilities (OR, 3.57; 95% CI, 1.94-6.55). The geographical location affected the odds of undergoing active surveillance. Specifically, New England patients were more likely to undergo active surveillance than patients in all other regions (P < .001 for all comparisons). Conversely, the odds of receiving active surveillance were lowest in the East South Central region (OR, 0.21; 95% CI, 0.11-0.39). Figure 2 shows the adjusted probabilities of active surveillance sorted in ascending order (from least likely to most likely). Table 3 shows the pseudo-R 2 values from the multilevel hierarchical mixed effects logistic regression. Patient characteristics explained 58.3% of the variation of receiving active surveillance. Hospital characteristics such as the facility type, facility location, and treatment volume contributed 10.7% of the variation. The individual facility, regardless of the hospital characteristics, explained 91.5% of the remaining variation. Unmeasured characteristics accounted for 2.6% of the variability in the use of active surveillance. Sensitivity analyses including 1) cTx and 2) cT2 patients showed results similar to those of the original cohort analysis (data not shown).
DISCUSSION
Because of several studies demonstrating comparable short-term survival rates and pathological outcomes among patients undergoing active surveillance versus immediate definitive therapy for low-risk prostate cancer, the use of active surveillance has increased in recent years. 24, 25 However, uncertainty surrounding the selection of individuals appropriate for active surveillance as well as criteria for progression to definitive therapy has limited the widespread adoption of active surveillance. 26 With the recent passage of US legislation aimed at standardizing validated, high-value clinical care, it is incumbent upon stakeholders, including urologists, administrators, and legislators, to identify and ultimately limit sources of nonclinical variation seen in active surveillance. 11 In this context, we used a large, national, hospital-based database to determine both rates and predictors of active surveillance in men 40 to 75 years old who had been diagnosed with low-risk prostate cancer. Our study has several noteworthy findings.
First, we found that the use of active surveillance for low-risk prostate cancer remained low at 12.3% among CoC-designated facilities between 2010 and 2014. Published literature on active-surveillance rates has been highly inconsistent. Previously published physician-based registry data suggest that active-surveillance rates may have been as high as 49% in men with low-risk prostate cancer for the years 2012 and 2013. 4, 5 Conversely, population-or hospital-based reports have shown active-surveillance rates as low as 15%, and these rates may be even lower when stricter selection criteria are used. 6, 7 With the criteria suggested by Klotz et al, 1 only 6.5% of the patients within the NCDB received active surveillance. 7 This discrepancy in results may originate from important differences between data sources. The NCDB is hospital-based and captures patients who are referred to a hospital practice for further management. Therefore, some cases of active surveillance may not appear in the NCDB because they are managed completely in an outpatient fashion. However, it is important to note that 50.8% of prostate cancer cases are captured in the NCDB, the majority of which are diagnosed in a community setting. 27 Moreover, a study comparing data from the NCDB and the Surveillance, Epidemiology, and End Results registry (a nationally representative population-based cancer registry) showed similar rates of treatment between the 2 data sets. 28 These observations provide compelling arguments for the representativeness of NCDB data. Regardless and most importantly, it is reassuring that the rate of active surveillance increased at a fast pace over the study period Original Article Original Article (2010-2014), and this is consistent with all reports from hospital-based, multi-institutional, collaborative, and population-based registries. 4, 5, 9 We found that rates of active surveillance were mostly influenced by several nonclinical factors such as the facility type and the treatment volume. Up to 91% of the unexplained variation in prostate cancer treatment was attributable to features of the treating facility. Although previous studies have documented similar rates of variation in active surveillance, this was largely attributed to clinical factors such as age and comorbidities. 5, 29, 30 To the best of our knowledge, our report is the first to document significant variation in activesurveillance rates attributable to hospital characteristics such as the geographic region, type, and volume; and to the institution itself. Several theories have been proposed regarding the etiology of nonclinical determinates of prostate cancer therapy type. For example, using a timetradeoff survey method to account for the influence of patient preference in predicting the treatment of localized prostate cancer, Sommers et al 31 found that the greatest predictor of treatment type was the treating physician's specialty; for example, patients seen by radiation oncologists were more likely to receive radiation therapy. Recently, Tyson et al 32 found impressive urologist-level variation for the probability of observation for low-risk prostate cancer. Similarly, several studies have found that physicians' preference for/familiarity with a particular treatment and/or diagnostic modality has a profound impact on cancer treatment. Lipitz-Snyderman et al 33 found that physicians who previously used unindicated imaging modalities for patients with early-stage prostate cancer had increased odds of using those same diagnostic tests for subsequent patients. These results suggest that physicians must do a better job of overcoming their ingrained tendencies by constantly assimilating evolving treatment algorithms into their practice patterns. Financial incentives, subconscious or overt, may also play a role in the treatment variation seen among patients with low-risk prostate cancer. For example, in a retrospective cohort study using Surveillance, Epidemiology, and End Results-Medicare data, Hoffman et al 9 found that just 19.9% of men with low-risk prostate cancer were observed, and the diagnosing urologist accounted for 16.1% of the variation in upfront treatment versus observation. Interestingly, patients were more likely to undergo definitive therapy if their urologist billed for the treatment in question. Similarly, increased use of radiation therapy has been reported among urologists with integrated intensity-modulated radiation therapy devices in comparison with those who do not, namely, academic medical centers. 34 This finding may in part be attributable to the significant fixed costs associated with the acquisition of devices such as the da Vinci Surgical System or a proton beam. 35, 36 Consequently, lower volume centers may feel pressured to pursue extirpative therapy over less invasive modalities to defray the costs of robot acquisition and upkeep. Other potential factors driving the observed variation in active-surveillance rates that cannot be addressed by the current data might include legal fears regarding the underestimation of prostate cancer aggressiveness, a family history of prostate cancer, and patient-related psychological factors. 9, 37 The aforementioned factors may explain why surveillance uptake is exceptionally low in the United States in comparison with other Western economies such as the European Union. 38, 39 Consequently, it will be important to tout the results of the many ongoing trials aimed at providing decision aids to men newly diagnosed with prostate cancer, which may help to mitigate some of the common misconceptions surrounding prostate cancer treatment and survival. 40 Our findings suggest that urologists have been critically poor at enrolling low-risk patients into activesurveillance protocols, and this is supported by past literature. For example, in a retrospective cohort study using Surveillance, Epidemiology, and End Results-Medicare data, Jacobs et al 41 found that the use of advancedtreatment technologies (eg, radical prostatectomy and/or intensity-modulated radiation therapy) among men with either low-risk prostate cancer (32%-44%; P < .001) or a high risk of noncancer mortality (36%-57%; P < .001) had actually increased between 2004 and 2009. Although the concept of active surveillance in its current form had yet to emerge during the study period, these trends are nonetheless concerning. As the gatekeepers of prostate cancer management and therapy, urologists must do their due diligence to use validated treatment nomograms that include shared decision making between the provider and the patient. 42 Moreover, our finding of significant variation in inter-institutional practice suggests that the institution at which one is treated matters as much as, if not more than, one's health status and beliefs regarding treatment selection. Unfortunately, similar trends have been found with respect to definitive therapy use among men with prostate cancer, and our results should, therefore, not come as a surprise. [43] [44] [45] Given the significant cost associated with episodes of surgical care in the United States (by some estimates more than $400 billion per year), the Centers for Medicare and Medicaid Services is likely to target the aforementioned variation in the near future with the end goal of minimizing the influence of nonclinical factors such as practice setting on treatment strategies. 46 Our findings also have important policy implications, particularly in the context of recent alternative payment model proposals by the Centers for Medicare and Medicaid Services. Starting in 2019, health care provider organizations participating in the Medicare Shared Savings Program will be subject to 2-sided risk, whereby they will be responsible for any costs exceeding predefined episode-of-care payment bundles. Given the proven costeffectiveness of active surveillance versus early intervention for low-risk prostate cancer, organizations may incentivize their providers to favor this management option for appropriate patients. 47 Similarly, under the provisions of the Medicare Access and CHIP Reauthorization Act of 2015, individual providers will be subject to a merit-based incentive payment system aimed to standardize care. 11 Radical prostatectomy, external-beam radiation therapy, and brachytherapy currently constitute acceptable treatment options for low-risk localized prostate cancer under NCCN guidelines. However, the combination of growing concern regarding the overtreatment of localized disease and a renewed emphasis on cost-conscious care suggests that active surveillance may emerge as the recommended first-line therapy for many prostate cancer patients. 3 It is imperative that professional organizations such as the American Urological Association and NCCN establish guidelines aimed at limiting nonclinical sources of variation in prostate cancer treatment. Our findings suggest that funneling care toward regional high-volume centers Original Article may lead to both improved standardization of care and eventual cost savings. 48 Our findings must be considered within the context of the study design. First, in addition to the limitations inherent to the NCDB's hospital-based data collection (as discussed previously), our study is limited by the retrospective nature of the cohort. An unmeasured treatment selection bias might have influenced our results. Second, CoC facilities tend to be larger, urban tertiary care centers, and they may not be representative of the general trends in the US population. 49 Finally, the variable used for the determination of the receipt of active surveillance does not distinguish between active surveillance and watchful waiting (NCDB, e-mail from April 12th 2016). That said, there is a distinct variable for patients who chose no treatment, which most closely approximates watchful waiting.
In conclusion, within this hospital-based cohort, the use of active surveillance for low-risk prostate cancer increased significantly over time. We found significant variation in the use of active surveillance. Most variation was attributable to facility-related factors such as the facility type, facility volume, and institution. Policies to achieve consistent and higher rates of active surveillance, when appropriate, should be a priority of professional societies and patient advocacy groups.
